Vectura strikes again as Sandoz expands VR315 deal
This article was originally published in Scrip
Vectura has signed another licensing deal for its mystery respiratory product, VR315 (thought widely to be a generic version of GlaxoSmithKline's Advair (fluticasone plus salmeterol) using Vectura's GyroHaler dry powder inhaler). The news that its European marketing partner Sandoz is to take on rest of world rights comes just days after the UK firm announced it had secured an unnamed partner for US development and commercialisation (scripintelligence.com, 03 August 2011).
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.